Event-Driven Stocks

ImmunityBio, Inc.

IBRXNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 4 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$113.3M$14.7M$622,000$240,000$139,000$21,000
Operating income−$256.0M−$344.2M−$362.3M−$351.3M−$86.3M−$18.6M
Net income−$351.4M−$413.6M−$583.2M−$416.6M−$346.8M−$18.4M
Total assets$501.9M$382.9M$504.5M$362.4M$468.9M$151.9M
Total liabilities$1.00B$871.1M$1.09B$812.2M$712.8M$34.5M
Equity−$500.5M−$489.1M−$587.0M−$447.3M−$242.2M$117.4M
EPS (diluted)$-0.38$-0.62$-1.15$-1.04$-0.89$-0.59
Shares out.853.4M674.0M435.8M397.9M109.3M98.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−226.0%
Net margin
−310.2%
Return on equity
70.2%
Return on assets
−70.0%
Return on capital (ROCE)
−58.2%
Liabilities / assets
199.5%
Debt / equity
—
Book value / share
$-0.59
Revenue growth (YoY)
668.3%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-24.85distress
Accruals / assets
−9.3%clean
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
49
/ 100
Profitability 20Growth 100Catalyst 33Earnings quality 67Financial strength 25

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 2 severe● 4 warning● 3 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026132.8M10.6-3.9%
Apr 30, 2026138.1M10.6-1.6%
Apr 15, 2026140.3M9.5+3.5%
Mar 31, 2026135.5M4.7+1.0%
Mar 13, 2026134.2M5.3+1.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.